NEW YORK (GenomeWeb News) – Proteome Sciences said today that it will collaborate with CHDI Foundation on research into protein biomarkers for Huntington's disease.
Under the collaboration, the London-based company will use its Tandem Mass Tag reagents to develop mass spectrometry-based high density protein expression maps in cell lines carrying different levels of the CAG-repeat genetic alteration linked to Huntington's.
The work will be done at Proteome Sciences' ISO 9001:2008 certified facility in Frankfurt. Financial and other terms of the deal were not disclosed.
"We are excited to implement a robust proteomic platform in support of our systems biology efforts at CHDI," Jamshid Arjomand, director of basic research at CHDI, said in a statement. "Proteome Sciences' expertise in this domain will provide an additional layer of information to help us and the wider HD research community probe the pathological mechanisms involved in this devastating disorder."
In addition to the CHDI project, Proteome Sciences has previously done research identifying blood-based protein biomarkers for measuring Huntington's progression, several of which are currently be evaluated as potential pharmacodynamic markers in University College London's Paddington Study.